For Patient Brochures and Patient Guides click on a product below:
Myriad myRisk Hereditary Cancer is a 28-gene panel for the identification of clinically significant mutations impacting inherited risks for eight important cancers. Blending genetic test status AND personal/family cancer history into clinically significant risk assessment and follow-up, the myRisk Hereditary Cancer test represents the next generation of cancer genetic testing.
Hereditary Breast and Ovarian Cancer
Hereditary Colorectal Cancer
COLARIS testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s
risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in
the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes.
EndoPredict is a second generation gene expression analysis used to determine the risk of metastasis with
endocrine therapy alone in patients with ER-positive HER2-negative primary breast cancer. Stratifying
patients into clear High and Low Risk categories, EndoPredict reliably predicts early and late metastases.
Prolaris is a molecular diagnostic test that measures the expression level of genes involved with
tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other
clinical parameters to determine prostate cancer aggressiveness. The Prolaris result provides
10-year risks for prostate cancer specific mortality in the biopsy setting or biochemical recurrence
in the post-prostatectomy setting.
Tumor BRACAnalysis CDx is a CE marked companion diagnostic tumor test for ovarian cancer patients.
This test can detect up to 50% more patients with mutations in the BRCA1 and BRCA2 genes. BRCA
mutation analysis is essential in ovarian cancer patients to identify the subset of women who are
most likely to benefit from PARP inhibitors.
BRACAnalysis is a companion diagnostic blood test for ovarian cancer patients, to detect germline
mutations in the BRCA1 and BRCA2 genes. BRCA mutation analysis is essential in ovarian cancer
patients to identify the subset of women who are most likely to benefit from PARP inhibitors.